Department of Biomedical Engineering, Johns Hopkins University, Baltimore, MD, USA.
Department of Mechanical Engineering, Johns Hopkins University, Baltimore, MD, USA.
Analyst. 2021 Apr 26;146(8):2475-2483. doi: 10.1039/d1an00039j.
The development of accelerated methods for pathogen identification (ID) and antimicrobial susceptibility testing (AST) for infectious diseases is necessary to facilitate evidence-based antibiotic therapy and reduce clinical overreliance on broad-spectrum antibiotics. Towards this end, droplet-based microfluidics has unlocked remarkably rapid diagnostic assays with single-cell and single-molecule resolution. Yet, droplet platforms invariably rely on testing purified bacterial samples that have been clinically isolated after lengthy (>16 h) plating. While plating-based clinical isolation is important for enriching and separating out bacteria from background in clinical samples and also facilitating buffer exchange, it creates a diagnostic bottleneck that ultimately precludes droplet-based methods from achieving significantly accelerated times-to-result. To alleviate this bottleneck, we have developed facile syringe filter-enabled strategies for bacterial separation, enrichment, and buffer exchange from urine samples. By selecting appropriately sized filter membranes, we separated bacterial cells from background particulates in urine samples and achieved up to 91% bacterial recovery after such 1-step filtration. When interfaced with droplet-based detection of bacterial cells, 1-step filtration improved the limit of detection for bacterial ID and quantification by over an order of magnitude. We also developed a facile buffer exchange strategy to prepare bacteria in urine samples for droplet-based AST that achieved up to 10-fold bacterial enrichment during buffer exchange. Our filtration strategies, can be easily integrated into droplet workflows, enable clinical isolation-free sample-to-answer ID and AST, and significantly accelerate the turnaround of standard infectious disease diagnostic workflows.
为了促进基于证据的抗生素治疗并减少临床对广谱抗生素的过度依赖,有必要开发用于传染病病原体鉴定(ID)和药敏试验(AST)的加速方法。为此,基于液滴的微流控技术为具有单细胞和单分子分辨率的快速诊断检测打开了新局面。然而,液滴平台始终依赖于测试经过临床分离后长时间(>16 小时)培养的纯化细菌样本。虽然基于平板的临床分离对于从临床样本中的背景中富集和分离细菌以及促进缓冲液交换很重要,但它会造成诊断瓶颈,从而最终阻止基于液滴的方法实现显著的加速结果时间。为了缓解这一瓶颈,我们开发了简便的注射器过滤器策略,用于从尿液样本中进行细菌分离、富集和缓冲液交换。通过选择适当尺寸的滤膜,我们从尿液样本中的背景颗粒中分离出细菌细胞,并在经过 1 步过滤后实现了高达 91%的细菌回收率。当与基于液滴的细菌细胞检测相结合时,1 步过滤将细菌 ID 和定量检测的检测限提高了一个数量级以上。我们还开发了一种简便的缓冲液交换策略,用于准备尿液样本中的细菌进行基于液滴的 AST,在缓冲液交换过程中实现了高达 10 倍的细菌富集。我们的过滤策略可以轻松集成到液滴工作流程中,实现无临床分离的样本到答案的 ID 和 AST,并显著加速标准传染病诊断工作流程的周转时间。